Peptide Therapy for Lyme Disease and Chronic Infections

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Chronic Lyme disease and post-infectious syndromes involve persistent immune dysregulation and inflammation. Thymosin Alpha-1 restores NK cell function and anti-pathogen immunity. BPC-157 reduces gut inflammation and systemic inflammatory burden. LL-37 has direct antimicrobial activity against Borrelia and other pathogens.

The Chronic Infection Challenge

Chronic Lyme disease and other persistent infections represent a significant clinical challenge. Whether due to persistent bacterial infection, immune dysregulation, or post-infectious syndrome, patients with chronic Lyme disease often experience debilitating symptoms — fatigue, joint pain, cognitive dysfunction, and neurological symptoms — that respond poorly to conventional antibiotic therapy. Peptide-based immune modulation offers a complementary approach that addresses the immune dysfunction that underlies many of these persistent symptoms.

Thymosin Alpha-1: Restoring Anti-Pathogen Immunity

Borrelia burgdorferi (the Lyme disease bacterium) and many other chronic pathogens evade immune clearance by suppressing NK cell activity and Th1 immune responses. Thymosin Alpha-1 directly addresses this by restoring NK cell function and promoting Th1 immunity — the arm of the immune system responsible for clearing intracellular pathogens. Clinical studies have shown Tα1 to improve outcomes in chronic hepatitis B and C, sepsis, and other chronic infections. Typical dosing: 1.6 mg subcutaneously twice weekly for 12–24 weeks.

LL-37: Direct Antimicrobial Activity

LL-37 is a human cathelicidin with broad-spectrum antimicrobial activity, including activity against Borrelia burgdorferi. In addition to its direct antimicrobial effects, LL-37 modulates the inflammatory response in infected tissue, promoting pathogen clearance while limiting excessive tissue damage. LL-37 can be administered intranasally or systemically.

BPC-157: Reducing Inflammatory Burden

Chronic infections are associated with significant systemic inflammation that contributes to many of the debilitating symptoms. BPC-157's anti-inflammatory and gut-healing properties can reduce the overall inflammatory burden, improving symptom severity even when the underlying infection cannot be fully eradicated. Many practitioners include BPC-157 as a foundational element of chronic Lyme treatment protocols.

Practical Protocol

A peptide-based chronic Lyme support protocol might include: Thymosin Alpha-1 (1.6 mg twice weekly) for immune restoration, BPC-157 (500 mcg daily) for anti-inflammatory and gut-healing effects, and LL-37 for antimicrobial support. This should be implemented under medical supervision and in conjunction with appropriate antibiotic therapy and other conventional treatments.